
- Oncology
- Exited
KaloBios is developing proprietary customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.
www.kalobios.comKaloBios is developing proprietary customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with cancer.
www.kalobios.com